Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M8,634Revenue $M934Net Margin (%)4.7Z-Score1.8
Enterprise Value $M11,029EPS $2.2Operating Margin %14.5F-Score3
P/E(ttm))163Cash Flow Per Share $3.6Pre-tax Margin (%)5.4Higher ROA y-yN
Price/Book11.710-y EBITDA Growth Rate %0Quick Ratio1.4Cash flow > EarningsY
Price/Sales7.35-y EBITDA Growth Rate %0Current Ratio1.5Lower Leverage y-yN
Price/Cash Flow11.8y-y EBITDA Growth Rate %23.5ROA % (ttm)1.8Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)8.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M63.7ROI % (ttm)2.6Gross Margin Increase y-yN

Gurus Latest Trades with SLXP

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SLXPAndreas Halvorsen 2014-06-30 Add0.74%$97.7 - $125.07
($110.33)
$ 135.5623%Add 86.19%2,889,303
SLXPJoel Greenblatt 2014-06-30 Sold Out -0.48%$97.7 - $125.07
($110.33)
$ 135.5623%Sold Out0
SLXPAndreas Halvorsen 2014-03-31 Buy 0.67%$88.8 - $114.64
($101.95)
$ 135.5633%New holding, 1551766 sh.1,551,766
SLXPJoel Greenblatt 2014-03-31 Buy 0.48%$88.8 - $114.64
($101.95)
$ 135.5633%New holding, 307445 sh.307,445
SLXPJoel Greenblatt 2013-09-30 Sold Out -0.36%$65.73 - $75.54
($68.97)
$ 135.5696%Sold Out0
SLXPJoel Greenblatt 2013-06-30 Buy 0.36%$47.72 - $66.83
($57.19)
$ 135.56137%New holding, 127495 sh.127,495
SLXPVanguard Health Care Fund 2013-03-31 Add0.08%$40.472 - $51.37
($47.96)
$ 135.56183%Add 22.44%2,147,945
SLXPJoel Greenblatt 2013-03-31 Sold Out -0.15%$40.472 - $51.37
($47.96)
$ 135.56183%Sold Out0
SLXPJoel Greenblatt 2012-12-31 Add0.06%$37.97 - $42.9
($40.82)
$ 135.56232%Add 75.81%63,399
SLXPNWQ Managers 2012-12-31 Sold Out -0.17%$37.97 - $42.9
($40.82)
$ 135.56232%Sold Out0
SLXPJoel Greenblatt 2012-09-30 Buy 0.1%$41.92 - $55.65
($47.44)
$ 135.56186%New holding, 36061 sh.36,061
SLXPNWQ Managers 2012-03-31 Reduce-0.14%$45.72 - $53.75
($46.12)
$ 135.56194%Reduce -40.33%656,533
SLXPNWQ Managers 2011-09-30 Add0.18%$26.18 - $40.9
($33.07)
$ 135.56310%Add 198.07%1,320,679
SLXPVanguard Health Care Fund 2011-09-30 Add0.09%$26.18 - $40.9
($33.07)
$ 135.56310%Add 55.43%1,554,300
SLXPJohn Paulson 2011-09-30 Sold Out -0.2056%$26.18 - $40.9
($33.07)
$ 135.56310%Sold Out0
SLXPJohn Paulson 2011-06-30 Add0.19%$34.69 - $40.57
($37.85)
$ 135.56258%Add 971.43%1,500,000
SLXPNWQ Managers 2011-06-30 Buy 0.09%$34.69 - $40.57
($37.85)
$ 135.56258%New holding, 443084 sh.443,084
SLXPGeorge Soros 2011-06-30 Sold Out $34.69 - $40.57
($37.85)
$ 135.56258%Sold Out0
SLXPJohn Paulson 2011-03-31 Buy 0.01%$31.61 - $48.03
($38.86)
$ 135.56249%New holding, 140000 sh.140,000
SLXPGeorge Soros 2011-03-31 Reduce$31.61 - $48.03
($38.86)
$ 135.56249%Reduce -95.44%5,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SLXP is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SLXP Andreas Halvorsen 2014-06-302,889,3034.541.6+86.19%
SLXP Vanguard Health Care Fund 2014-06-301,824,5452.860.59-10.25%
SLXP Joel Greenblatt 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


SLXP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
LOGAN CAROLYN JPresident & CEO 2014-06-26Sell53,057$123.3811.61view
Scruggs Rick DExecutive Vice President 2014-05-16Sell900$105.6730.32view
D ALONZO THOMASDirector 2014-04-22Sell11,530$110.8924.19view
Scruggs Rick DExecutive Vice President 2014-03-04Sell1,319$110.6624.44view
CHAPPELL JOHN FDirector 2014-03-04Sell10,000$112.222.74view
D ALONZO THOMASDirector 2014-01-10Sell12,050$91.8349.96view
DERBYSHIRE ADAM CEVP Finance/CFO 2014-01-09Sell30,001$91.4850.54view
Forbes William PEVP Research&Devel & CDO 2014-01-08Sell8,000$90.0652.91view
Scruggs Rick DExecutive Vice President 2014-01-07Sell8,463$88.3155.94view
KEANE WILLIAM PDirector 2014-01-07Sell22,500$88.3155.94view

Press Releases about SLXP :

Quarterly/Annual Reports about SLXP:

News about SLXP:

Articles On GuruFocus.com
Bill Ackman and Valeant Could Sweeten Allergan Deal By $15 A Share Oct 10 2014 
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
Joel Greenblatt's Gotham Capital Top 5 New Stocks May 16 2014 
Weekly CFO Sells Highlight: FII, SLXP, CCK, VCI, WDC, STMP Dec 31 2012 
Weekly Guru Bargains Highlights: HMSY, FB, TSU, SLXP, ANR Oct 29 2012 
Value Shop Nuveen Investments Reports Second Quarter Portfolio Aug 19 2011 
Hedge Fund Giant John Paulson Reports Q2 Portfolio Aug 15 2011 
Salix Pharmaceuticals Ltd. (SLXP) President & CEO Carolyn J Logan sells 14,000 Shares Sep 23 2010 
Salix Pharmaceuticals Ltd. (SLXP) EVP Finance/CFO Adam C Derbyshire sells 5,000 Shares Dec 11 2009 
Salix Pharmaceuticals Ltd. (SLXP) EVP Finance/CFO Adam C Derbyshire sells 5,000 Shares Dec 02 2009 

More From Our Partners
Making Money With Charles Payne: 10/17/14 Oct 17 2014 - FOXBUSINESS

More From Other Websites
Salix Pharmaceuticals Announces 3Q2014 Financial Results Conference Call and Webcast Oct 23 2014
Salix’s TARGET 3 Study Examines the Safety and Efficacy of Repeat Treatment with Rifaximin 550 mg... Oct 21 2014
7:02 am Salix Pharma's TARGET 3 Study examines the safety and efficacy of repeat treatment with... Oct 21 2014
Salix’s TARGET 3 Study Examines the Safety and Efficacy of Repeat Treatment with Rifaximin 550 mg... Oct 21 2014
SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 17 2014
Salix Pharmaceuticals Outlines Data Presentations at American College of Gastroenterology 2014... Oct 17 2014
Salix Pharmaceuticals Outlines Data Presentations at American College of Gastroenterology 2014... Oct 17 2014
AbbVie sours on $55B Shire deal after tax changes Oct 16 2014
AbbVie Board To Shareholders: Vote No On Shire Buy Oct 16 2014
Shire Falls, AbbVie Questioned On Buyout Backtrack Oct 15 2014
[$$] Italy's Cosmo Plans Relocation to Luxembourg Oct 15 2014
Cosmo Plans Management Move in Search of Irish Corporate Charm Oct 15 2014
Pharming and Swedish Orphan Biovitrum Amend and Extend Ruconest Distribution Agreement Oct 12 2014
Inversion Vitriol Vs. Drug Consolidation Oct 10 2014
Allergan Raises Outlook amidst Valeant Takeover Attempts Oct 10 2014
Salix's Rectal Foam Uceris Receives Final FDA Approval Oct 09 2014
Allergan Steeply Raises Guidance, Taunts Valeant Oct 09 2014
Takeover target Allergan raises guidance Oct 09 2014
SALIX PHARMACEUTICALS LTD Files SEC form 8-K, Other Events, Financial Statements and Exhibits Oct 08 2014
Allergan & Valeant & Actavis & Salix: Can This Love Quadrilateral Work? Oct 08 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK